Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9

@inproceedings{Lidegaard2011RiskOV,
  title={Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9},
  author={\Ojvind Lidegaard and Lars Hougaard Nielsen and Charlotte Wessel Skovlund and Finn E Skjeldestad and Ellen Christine Leth L\okkegaard},
  booktitle={BMJ},
  year={2011}
}
OBJECTIVE To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose. DESIGN National historical registry based cohort study. SETTING Four registries in Denmark. PARTICIPANTS Non-pregnant Danish women aged 15-49 with no history of thrombotic disease and followed from January 2001 to December 2009. MAIN OUTCOME MEASURES Relative and absolute risks of first time venous thromboembolism. RESULTS Within 8,010,290… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Connections & Topics

Mentioned Connections BETA
If oral contraceptives with desogestrel , gestodene , or drospirenone are anticipated to increase the risk of venous thromboembolism sixfold and those with levonorgestrel threefold , and the absolute risk of venous thromboembolism in current users of the former group is on average 10 per 10,000 women years , then 2000 women would need to shift from using oral contraceptives with desogestrel , gestodene , or drospirenone to those with levonorgestrel to prevent one event of venous thromboembolism in one year . CONCLUSION .
With users of oral contraceptives with levonorgestrel as reference and after adjusting for length of use , the rate ratio of confirmed venous thromboembolism for users of oral contraceptives with desogestrel was 2.2 ( 1.7 to 3.0 ) , with gestodene was 2.1 ( 1.6 to 2.8 ) , and with drospirenone was 2.1 ( 1.6 to 2.8 ) .
After adjustment for length of use , users of oral contraceptives with desogestrel , gestodene , or drospirenone were at least at twice the risk of venous thromboembolism compared with users of oral contraceptives with levonorgestrel .
If oral contraceptives with desogestrel , gestodene , or drospirenone are anticipated to increase the risk of venous thromboembolism sixfold and those with levonorgestrel threefold , and the absolute risk of venous thromboembolism in current users of the former group is on average 10 per 10,000 women years , then 2000 women would need to shift from using oral contraceptives with desogestrel , gestodene , or drospirenone to those with levonorgestrel to prevent one event of venous thromboembolism in one year . CONCLUSION .
With users of oral contraceptives with levonorgestrel as reference and after adjusting for length of use , the rate ratio of confirmed venous thromboembolism for users of oral contraceptives with desogestrel was 2.2 ( 1.7 to 3.0 ) , with gestodene was 2.1 ( 1.6 to 2.8 ) , and with drospirenone was 2.1 ( 1.6 to 2.8 ) .
After adjustment for length of use , users of oral contraceptives with desogestrel , gestodene , or drospirenone were at least at twice the risk of venous thromboembolism compared with users of oral contraceptives with levonorgestrel .
Compared with non - users of hormonal contraception , the relative risk of confirmed venous thromboembolism in users of oral contraceptives containing 30 - 40 µg ethinylestradiol with levonorgestrel was 2.9 ( 95% confidence interval 2.2 to 3.8 ) , with desogestrel was 6.6 ( 5.6 to 7.8 ) , with gestodene was 6.2 ( 5.6 to 7.0 ) , and with drospirenone was 6.4 ( 5.4 to 7.5 ) .
Compared with non - users of hormonal contraception , the relative risk of confirmed venous thromboembolism in users of oral contraceptives containing 30 - 40 µg ethinylestradiol with levonorgestrel was 2.9 ( 95% confidence interval 2.2 to 3.8 ) , with desogestrel was 6.6 ( 5.6 to 7.8 ) , with gestodene was 6.2 ( 5.6 to 7.0 ) , and with drospirenone was 6.4 ( 5.4 to 7.5 ) .
Compared with non - users of hormonal contraception , the relative risk of confirmed venous thromboembolism in users of oral contraceptives containing 30 - 40 µg ethinylestradiol with levonorgestrel was 2.9 ( 95% confidence interval 2.2 to 3.8 ) , with desogestrel was 6.6 ( 5.6 to 7.8 ) , with gestodene was 6.2 ( 5.6 to 7.0 ) , and with drospirenone was 6.4 ( 5.4 to 7.5 ) .
Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses : Danish cohort study , 2001 - 9 . OBJECTIVE .
To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose .
Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses : Danish cohort study , 2001 - 9 . OBJECTIVE .
To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose .
Compared with non - users of hormonal contraception , the relative risk of confirmed venous thromboembolism in users of oral contraceptives containing 30 - 40 µg ethinylestradiol with levonorgestrel was 2.9 ( 95% confidence interval 2.2 to 3.8 ) , with desogestrel was 6.6 ( 5.6 to 7.8 ) , with gestodene was 6.2 ( 5.6 to 7.0 ) , and with drospirenone was 6.4 ( 5.4 to 7.5 ) .
Compared with non - users of hormonal contraception , the relative risk of confirmed venous thromboembolism in users of oral contraceptives containing 30 - 40 µg ethinylestradiol with levonorgestrel was 2.9 ( 95% confidence interval 2.2 to 3.8 ) , with desogestrel was 6.6 ( 5.6 to 7.8 ) , with gestodene was 6.2 ( 5.6 to 7.0 ) , and with drospirenone was 6.4 ( 5.4 to 7.5 ) .
Compared with non - users of hormonal contraception , the relative risk of confirmed venous thromboembolism in users of oral contraceptives containing 30 - 40 µg ethinylestradiol with levonorgestrel was 2.9 ( 95% confidence interval 2.2 to 3.8 ) , with desogestrel was 6.6 ( 5.6 to 7.8 ) , with gestodene was 6.2 ( 5.6 to 7.0 ) , and with drospirenone was 6.4 ( 5.4 to 7.5 ) .
All Topics